clinical trial · NCT06025344
A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml)
TrippBio, Inc.·phase1·completed·n = 14
Relative BioavailabilityPanCytoVir™ 100 mg/mL oral suspensionProbenecid 500 mg
brief summary
An open-label, balanced, randomized, two-treatment, two-sequence, two-period, crossover, single dose oral relative bioavailability study of a novel PanCytoVir™ oral suspension (100 mg/mL) versus probenecid 500 mg tablets in normal healthy, adult, human subjects under fasting conditions.
started
Sep 1, 2024
primary completion
Sep 30, 2024
completion
Oct 15, 2024
last updated
Nov 21, 2024
official title
A Single Dose Oral Bioavailability Study of PanCytoVir™ Oral Suspension (100 mg/ml) 1000 mg Versus Probenecid 500 mg Tablets, 1000 mg (2 X 500 mg) in Healthy, Adult, Human Subjects Under Fasting Conditions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol